BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34637337)

  • 1.
    Wagner AJ; Ravi V; Riedel RF; Ganjoo K; Van Tine BA; Chugh R; Cranmer L; Gordon EM; Hornick JL; Du H; Grigorian B; Schmid AN; Hou S; Harris K; Kwiatkowski DJ; Desai NP; Dickson MA
    J Clin Oncol; 2021 Nov; 39(33):3660-3670. PubMed ID: 34637337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Trial of
    Wagner AJ; Ravi V; Riedel RF; Ganjoo K; Van Tine BA; Chugh R; Cranmer L; Gordon EM; Hornick JL; Du H; Ding L; Schmid AN; Navarro WH; Kwiatkowski DJ; Dickson MA
    J Clin Oncol; 2024 May; 42(13):1472-1476. PubMed ID: 38427923
    [No Abstract]   [Full Text] [Related]  

  • 3. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
    Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
    Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
    Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
    J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
    Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
    Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
    Benson C; Vitfell-Rasmussen J; Maruzzo M; Fisher C; Tunariu N; Mitchell S; Al-Muderis O; Thway K; Larkin J; Judson I
    Anticancer Res; 2014 Jul; 34(7):3663-8. PubMed ID: 24982384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).
    Bergamo F; Maruzzo M; Basso U; Montesco MC; Zagonel V; Gringeri E; Cillo U
    World J Surg Oncol; 2014 Feb; 12():46. PubMed ID: 24575738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I/II Investigation of Safety and Efficacy of Nivolumab and
    Gordon EM; Angel NL; Omelchenko N; Chua-Alcala VS; Moradkhani A; Quon D; Wong S
    Anticancer Res; 2023 May; 43(5):1993-2002. PubMed ID: 37097693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
    Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
    Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.
    Scheppach W; Reissmann N; Sprinz T; Schippers E; Schoettker B; Mueller JG
    World J Gastroenterol; 2013 Mar; 19(10):1657-60. PubMed ID: 23539498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
    Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
    Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.
    Raimondi A; Colombo F; Pintarelli G; Morosi C; Renne SL; Frezza AM; Saponara M; Dei Tos AP; Mazzocchi A; Provenzano S; Casali PG; Stacchiotti S
    Anticancer Drugs; 2018 Jul; 29(6):589-595. PubMed ID: 29668485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
    Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HMB-45 negative multifocal malignant perivascular epithelioid cell tumor of the soft tissue responding to sirolimus: First case report from India.
    Kapoor A; Beniwal S; Singhal MK; Kumar N; Kumar V; Kumar HS
    J Cancer Res Ther; 2015; 11(4):1036. PubMed ID: 26881640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
    Abu-Khalaf MM; Baumgart MA; Gettinger SN; Doddamane I; Tuck DP; Hou S; Chen N; Sullivan C; Lezon-Geyda K; Zelterman D; Hatzis C; Deshpande H; Digiovanna MP; Azodi M; Schwartz PE; Harris LN
    Cancer; 2015 Jun; 121(11):1817-26. PubMed ID: 25649370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
    Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
    JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.
    Stacchiotti S; Provenzano S; Dagrada G; Negri T; Brich S; Basso U; Brunello A; Grosso F; Galli L; Palassini E; Libertini M; Colia V; Gronchi A; Dei Tos AP; Crippa F; Morosi C; Pilotti S; Casali PG
    Ann Surg Oncol; 2016 Sep; 23(9):2735-44. PubMed ID: 27334221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An orbital perivascular epithelioid cell tumor in a 7-year-old boy: case report and review of the literature.
    Varan A; Bayhan T; Kiratli H; Özoğul E; Kösemehmetoğlu K; Bulut E; Akyüz C
    J AAPOS; 2017 Aug; 21(4):325-328.e1. PubMed ID: 28576480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial.
    Gonzalez-Angulo AM; Meric-Bernstam F; Chawla S; Falchook G; Hong D; Akcakanat A; Chen H; Naing A; Fu S; Wheler J; Moulder S; Helgason T; Li S; Elias I; Desai N; Kurzrock R
    Clin Cancer Res; 2013 Oct; 19(19):5474-84. PubMed ID: 24089446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.